Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond
Alongside positive and negative symptomatology, deficits in working memory, attention, selective learning processes, and executive function have been widely documented in schizophrenia spectrum psychosis. These cognitive abnormalities are strongly associated with impairment across multiple function...
Saved in:
Main Authors: | John L. Waddington (Author), Xuechu Zhen (Author), Colm M. P. O'Tuathaigh (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Antipsychotics of New Generation: Where Are We now?
by: Tatiana V. Lipina, et al.
Published: (2021) -
Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder
by: Joanna Moncrieff, et al.
Published: (2020) -
The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023) -
Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis
by: Seyed Ghafur Mousavi, et al.
Published: (2013) -
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
by: Lally J, et al.
Published: (2016)